Phathom Pharmaceuticals Inc’s filing revealed that its CFO and CBO Henderson Molly unloaded Company’s shares for reported $43371.0 on Jan 21 ’25. In the deal valued at $6.59 per share,6,583 shares were sold. As a result of this transaction, Henderson Molly now holds 93,546 shares worth roughly $0.57 million.
Then, Nabulsi Azmi sold 7,886 shares, generating $51,957 in total proceeds. Upon selling the shares at $6.59, the Chief Operating Officer now owns 233,390 shares.
Before that, Curran Terrie sold 19,109 shares. Phathom Pharmaceuticals Inc shares valued at $125,884 were divested by the President and Chief Executive at a price of $6.59 per share. As a result of the transaction, Curran Terrie now holds 360,465 shares, worth roughly $2.18 million.
Stifel initiated its Phathom Pharmaceuticals Inc [PHAT] rating to a Buy in a research note published on May 03, 2024; the price target was $24. A number of analysts have revised their coverage, including Needham’s analysts, who remained covering the stock and in early January has reiterated a ‘”a Buy”‘ rating for it. H.C. Wainwright began covering PHAT with “Buy” recommendation on August 09, 2023. Evercore ISI revised its rating on May 11, 2023. It rated PHAT as “an Outperform” which previously was an “an In-line”.
Price Performance Review of PHAT
On Tuesday, Phathom Pharmaceuticals Inc [NASDAQ:PHAT] saw its stock jump 7.46% to $6.05. Over the last five days, the stock has lost -3.20%. Phathom Pharmaceuticals Inc shares have fallen nearly -25.49% since the year began. Nevertheless, the stocks have fallen -9.16% over the past one year. While a 52-week high of $19.71 was reached on 01/02/25, a 52-week low of $5.58 was recorded on 02/04/25. SMA at 50 days reached $7.73, while 200 days put it at $11.74.
Levels Of Support And Resistance For PHAT Stock
The 24-hour chart illustrates a support level at 5.63, which if violated will result in even more drops to 5.20. On the upside, there is a resistance level at 6.27. A further resistance level may holdings at 6.48. The Relative Strength Index (RSI) on the 14-day chart is 36.65, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.70, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 65.57%. Stochastics %K at 13.62% indicates the stock is a buying.
How much short interest is there in Phathom Pharmaceuticals Inc?
A steep rise in short interest was recorded in Phathom Pharmaceuticals Inc stocks on 2025-01-15, growing by 72142.0 shares to a total of 14.2 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 14.13 million shares. There was a rise of 0.51%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 13, 2023 when Craig Hallum began covering the stock and recommended ‘”a Buy”‘ rating along with a $21 price target.
